Even if you have previously told us how you would like to hear from us and/or you have supported us for many years, new data protection legislation requires you to provide your explicit consent in order for us to continue to contact you in the ways that are important to you.
Please use this form to tell us your preferences. You can also change your mind at any time – you will find further details about how to do this below. In the future, we will only contact you about the areas of our work you choose via the communication methods you prefer. Please complete all fields.
Orphazyme plans to meet with the US Food and Drug Administration (FDA) to discuss the pathway forward during the Summer and will provide an update after it has received written comments from the FDA...Read more
CTD Holdings, Inc. (OTCQB: CTDH)("CTD" or the "Company"), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that it closed its previously announced private placement of securities with a group of institutional and accredited investors that included directors and officers of the Company.Read more